CA2448506A1 - Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans - Google Patents

Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans Download PDF

Info

Publication number
CA2448506A1
CA2448506A1 CA002448506A CA2448506A CA2448506A1 CA 2448506 A1 CA2448506 A1 CA 2448506A1 CA 002448506 A CA002448506 A CA 002448506A CA 2448506 A CA2448506 A CA 2448506A CA 2448506 A1 CA2448506 A1 CA 2448506A1
Authority
CA
Canada
Prior art keywords
ser
leu
prevention
dental caries
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002448506A
Other languages
English (en)
French (fr)
Inventor
Wenyuan Shi
Sherie L. Morrison
Kham Trinh
Letitia Wims
Li Chen
Maxwell H. Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2448506A1 publication Critical patent/CA2448506A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002448506A 2001-06-15 2002-06-11 Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans Abandoned CA2448506A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/881,823 US20020068066A1 (en) 1999-08-20 2001-06-15 Method for the treatment and prevention of dental caries
US09/881,823 2001-06-15
PCT/US2002/018692 WO2002102975A2 (en) 2001-06-15 2002-06-11 Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans

Publications (1)

Publication Number Publication Date
CA2448506A1 true CA2448506A1 (en) 2002-12-27

Family

ID=25379292

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002448506A Abandoned CA2448506A1 (en) 2001-06-15 2002-06-11 Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans

Country Status (6)

Country Link
US (1) US20020068066A1 (enExample)
EP (1) EP1434799A4 (enExample)
JP (1) JP2004536824A (enExample)
AU (1) AU2002318342A2 (enExample)
CA (1) CA2448506A1 (enExample)
WO (1) WO2002102975A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569542B2 (en) 1999-08-20 2009-08-04 The Regents Of The University Of California Anti-microbial targeting chimeric pharmaceutical
US20030143234A1 (en) * 1999-08-20 2003-07-31 Wenyuan Shi Anti-microbial targeting chimeric pharmaceutical
US7875598B2 (en) * 2004-03-04 2011-01-25 The Regents Of The University Of California Compositions useful for the treatment of microbial infections
WO2008030988A2 (en) 2006-09-06 2008-03-13 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof
CN101622271B (zh) 2007-01-16 2014-08-27 加利福尼亚大学董事会 抗微生物肽
AU2014203172B2 (en) * 2010-02-24 2016-03-10 Immunogen, Inc. Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
TWI796132B (zh) 2010-02-24 2023-03-11 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
CL2011003002A1 (es) * 2011-11-25 2012-05-25 Univ Pontificia Catolica Chile Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
WO2016049183A1 (en) * 2014-09-24 2016-03-31 Aerpio Therapeutics, Inc. Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
WO2018017714A1 (en) * 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6046037A (en) * 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
AU756242B2 (en) * 1998-08-21 2003-01-09 Regents Of The University Of California, The Monoclonal antibodies specific for streptococcus mutans, and uses thereof
WO2002015931A1 (en) * 2000-08-24 2002-02-28 Washington Dental Service Immunologic method for the prevention of dental caries

Also Published As

Publication number Publication date
US20020068066A1 (en) 2002-06-06
AU2002318342A2 (en) 2003-01-02
WO2002102975A3 (en) 2004-04-15
JP2004536824A (ja) 2004-12-09
EP1434799A2 (en) 2004-07-07
WO2002102975A2 (en) 2002-12-27
EP1434799A4 (en) 2005-10-05

Similar Documents

Publication Publication Date Title
Abiko Passive immunization against dental caries and periodontal disease: development of recombinant and human monoclonal antibodies
US7078492B2 (en) Human antipneumococcal antibodies from non-human animals
CA2303202C (en) Amino acid sequences for therapeutical and prophylactic applications to diseases due to clostridium difficile toxins
US6417429B1 (en) Transgenic plants expressing assembled secretory antibodies
US8986990B2 (en) Human antibodies against Pseudomonas aeruginosa LPS
AU7287098A (en) Human monoclonal antibodies to epidermal growth factor receptor
JPH06501152A (ja) 動物およびヒトにおける感染の治療および予防用の新規な抗体
US20110177087A1 (en) Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse
CA2461989C (en) Method for treating multiple myeloma
US20030028913A1 (en) Method of use of transgenic plant expressed antibodies
US20020068066A1 (en) Method for the treatment and prevention of dental caries
WO2002015931A9 (en) Immunologic method for the prevention of dental caries
AU2007216785B2 (en) Human Antibodies Against Pseudomonas Aeruginosa LPS Derived from Transgenic Xenomouse
AU2001288866B2 (en) Human antibodies against pseudomonas aeruginosa LPS derived from transgenic xenomouse
JP2002114709A (ja) 虫歯予防剤
MXPA00002491A (en) Amino acid sequences for therapeutical and prophylactic applications to diseases due to clostridium difficile
AU2001288866A1 (en) Human antibodies against pseudomonas aeruginosa LPS derived from transgenic xenomouse
HK1031740B (en) Method of identifying binding site domains that retain the capacity of binding to an epitop
HK1031740A1 (en) Method of identifying binding site domains that retain the capacity of binding to an epitop

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead